Skip to main
PODD
PODD logo

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 38 analyst ratings
Buy
Strong Buy 32%
Buy 45%
Hold 16%
Sell 0%
Strong Sell 8%

Bulls say

Insulet's recent financial performance showcases strong growth, with global Omnipod sales increasing by 26% year-over-year on an underlying basis and reporting total sales of $2.07 billion for 2024, marking a 22% year-over-year increase. The company's ability to attract new patients significantly contributes to its positive momentum, especially as over 85% of new U.S. starts originate from multiple daily injections (MDI), highlighting the Omnipod's competitive positioning against rivals. Additionally, Insulet's market leadership is reinforced by stable global utilization rates and the successful adoption of the technologically advanced Omnipod 5 system, which offers broad compatibility with smartphones and has the potential to further accelerate growth in the diabetes management market.

Bears say

Insulet's operating margins have declined by 240 basis points year-over-year, reflecting the company's need to enhance operational efficiency amid competitive pressures. The projected Drug Delivery revenue declines of 45-55% year-over-year further highlight significant challenges in that segment, which could jeopardize overall sales growth and hinder profitability. Additionally, Insulet's reliance on third-party intermediaries for distribution increases operational risk and may lead to slower business growth, particularly if competitors introduce superior diabetes management solutions.

Insulet (PODD) has been analyzed by 38 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 45% recommend Buy, 16% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 38 analysts, Insulet (PODD) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $216.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $216.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.